Effect of normobaric intermittent hypoxia-hyperoxia in patients with post-acute-COVID-19 syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00031515

Enrollment

Registered

2023-06-14

Start date

2023-04-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-acute COVID Syndrom

Interventions

Group 1: Intervention group: undergo the intermittent hypoxic-hyperoxic exposure program (6 sessions per week for 3 weeks) in addition to standard care Group 2: Control group: undergo sham exposure (n

Eligibility

Sex/Gender

All

Age

30 Years to 69 Years

Inclusion criteria

Inclusion criteria: • Persistent COVID-19 related symptoms at least 4 weeks after the manifestation of the first acute symptoms • At least 30 days since recovery from clinical signs or medical discharge (if they have been hospitalized due to acute COVID-19 syndrome)

Exclusion criteria

Exclusion criteria: • Tested positive to COVID-19 • The need of intensive care • Current smoker and excessive use of alcohol or drugs • Pregnancy • Mental disease (e.g., MCI, dementia, schizophrenia, severe depression) • Uncontrolled cardiovascular disease (e.g., hypertension, angina pectoris, heart failure, arrhythmia) • Uncontrolled diabetes • Chronic renal dysfunction • Severe non-cardiac diseases such as cancer, anaemia that limit participation in the study • Inability to accept the procedure of breathing through a face-mask • Need for continuous or intermittent oxygen therapy • Exposure to altitudes >1500m in the last 3 months • Exacerbation of chronic diseases, requiring a change in patient management • Taking part in less than 75% of the total sessions planned

Design outcomes

Primary

Measure	Time frame
One day prior (pre-test) and two days after (post-test) the start and end of the intervention, respectively: Trait Fatigue as well as motor performance fatique and perceived motor performance fatigue (via Sit-to-Stand Test, 15-point Borg Scale, Borg's category ratio-10 Scale, 11-point Feeling-Scale, 6-point felt arousal Scale, Fatigue Severity Scale, Fatigue Scale for Motor and Cognitvie Function)	—

Measure

Time frame

One day prior (pre-test) and two days after (post-test) the start and end of the intervention, respectively: Trait Fatigue as well as motor performance fatique and perceived motor performance fatigue (via Sit-to-Stand Test, 15-point Borg Scale, Borg's category ratio-10 Scale, 11-point Feeling-Scale, 6-point felt arousal Scale, Fatigue Severity Scale, Fatigue Scale for Motor and Cognitvie Function)

—

Secondary

Measure	Time frame
One day prior (pre-test) and two days after (post-test) the start and end of the intervention, respectively: i) Quality of life and psycho-emotional state (via 12-Item Health Survey, Depression, Anxiety and Stress Scale-21, Beck Depression Inventory II, Pittsburgh Sleep Qiality Index) ii) Executive functions (via Go no Go Task, Simon-Task, Trail Making Test A+B, Sternberg Test, Digit Span Backwards Task) iii) Walking distance in 6-minute walk test iv) Handgrip strength (via isometric hand grip dynamometre) v) Pulmonary function vi) Blood parameters (IL-10, IL-6, TNF-1a, CRP-2, CRP-1 genotype). Immediately before and 10 minutes as well as 4.5 hours after the first intervention: Erythropoetin (blood serum)	—

Measure

Time frame

One day prior (pre-test) and two days after (post-test) the start and end of the intervention, respectively: i) Quality of life and psycho-emotional state (via 12-Item Health Survey, Depression, Anxiety and Stress Scale-21, Beck Depression Inventory II, Pittsburgh Sleep Qiality Index) ii) Executive functions (via Go no Go Task, Simon-Task, Trail Making Test A+B, Sternberg Test, Digit Span Backwards Task) iii) Walking distance in 6-minute walk test iv) Handgrip strength (via isometric hand grip dynamometre) v) Pulmonary function vi) Blood parameters (IL-10, IL-6, TNF-1a, CRP-2, CRP-1 genotype). Immediately before and 10 minutes as well as 4.5 hours after the first intervention: Erythropoetin (blood serum)

—

Countries

Germany

Contacts

Public ContactLutz Schega

Otto-von-Guericke-Universität Magdeburg

lutz.schega@ovgu.de09316756126

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026